Skip to main content
ARS Home » Research » Publications at this Location » Publication #254570

Title: Lactobacillus salivarius 1077 (NRRL B-50053) bacteriocin

item Seal, Bruce
item Stern, Norman
item Svetoch, Edward
item Eruslanov, Boris
item Levchuk, Vladimir
item Perelygin, Vladimir
item Mitsevich, Evgeny
item Mitsevich, Irina
item Stepanshin, Juri
item Dyatlov, Ivan

Submitted to: Federation of European Microbiological Societies Microbiology Letters
Publication Type: Abstract Only
Publication Acceptance Date: 7/1/2010
Publication Date: 9/22/2010
Citation: Seal, B.S., Stern, N.J., Svetoch, E.A., Eruslanov, B.V., Levchuk, V.P., Perelygin, V.V., Mitsevich, E.V., Mitsevich, I.P., Stepanshin, J., Dyatlov, I. 2010. Lactobacillus salivarius 1077 (NRRL B-50053) bacteriocin . Federation of European Microbiological Societies Microbiology Letters.

Interpretive Summary:

Technical Abstract: Lactobacillus salivarius 1077 (NRRL B-50053) was isolated from poultry intestinal materials after demonstrating in-vitro anti-Campylobacter jejuni activity. The isolate was then used for in-vitro fermentation. The protein content of the cell-free supernatant from the spent medium was precipitated by ammonium sulfate and dialyzed to produce the crude antimicrobial preparation. The bacteriocin (BCN)-like sensitivity to proteolytic enzymes and resistance to lysozyme, lipase and 100o C was observed with this preparation. The polypeptide was further purified by gel-filtration, ion-exchange and hydrophobic-interaction chromatography. MALDI TOF MS, Edman degradation and iso-electro focusing were used to characterize its 3,454 Da molecular weight, the amino acid sequence of its 37 residue components and the 9.1 iso-electric point of the BCN. BCN L-1077 contained the Class II BCN signature N-terminus sequence of YGNGV. Minimum inhibitory concentrations (MIC) of BCN L-1077 against 33 bacterial isolates (both Gram-negative and Gram-positive) ranged from 0.09 to 1.5 mg/ml. Subsequently, the therapeutic benefit of BCN L-1077 was demonstrated in market-age (40 to 43 day old) broiler chickens colonized with both C. jejuni and Salmonella enteritidis. As compared with untreated control birds, both C. jejuni and S. enteritidis in colonized ceca were diminished by > 4 log10 and, S. enteritidis in both the liver and spleen of treated birds were reduced by 6 to 8 log10/gm over the non-treated control birds. BCN L-1077 appears to hold promise in controlling C. jejuni/S. enteritidis in commercial broiler chickens.